These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18687633)

  • 1. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
    VanMeter AJ; Rodriguez AS; Bowman ED; Jen J; Harris CC; Deng J; Calvert VS; Silvestri A; Fredolini C; Chandhoke V; Petricoin EF; Liotta LA; Espina V
    Mol Cell Proteomics; 2008 Oct; 7(10):1902-24. PubMed ID: 18687633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot characterization of human lung NSCLC by protein pathway activation mapping.
    Zupa A; Improta G; Silvestri A; Pin E; Deng J; Aieta M; Musto P; Nitti D; Mammano E; Liotta L; Belluco C; Wulfkuhle J; Petricoin E
    J Thorac Oncol; 2012 Dec; 7(12):1755-1766. PubMed ID: 23154546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
    Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
    Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites.
    Fan YX; Wong L; Deb TB; Johnson GR
    J Biol Chem; 2004 Sep; 279(37):38143-50. PubMed ID: 15231819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041.
    Tong J; Taylor P; Peterman SM; Prakash A; Moran MF
    Mol Cell Proteomics; 2009 Sep; 8(9):2131-44. PubMed ID: 19531499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 10. HGF-independent potentiation of EGFR action by c-Met.
    Dulak AM; Gubish CT; Stabile LP; Henry C; Siegfried JM
    Oncogene; 2011 Aug; 30(33):3625-35. PubMed ID: 21423210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor-like repeats of thrombospondins activate phospholipase Cgamma and increase epithelial cell migration through indirect epidermal growth factor receptor activation.
    Liu A; Garg P; Yang S; Gong P; Pallero MA; Annis DS; Liu Y; Passaniti A; Mann D; Mosher DF; Murphy-Ullrich JE; Goldblum SE
    J Biol Chem; 2009 Mar; 284(10):6389-402. PubMed ID: 19129184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling.
    Li X; Huang Y; Jiang J; Frank SJ
    Cell Signal; 2008 Nov; 20(11):2145-55. PubMed ID: 18762250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer.
    Valley CC; Arndt-Jovin DJ; Karedla N; Steinkamp MP; Chizhik AI; Hlavacek WS; Wilson BS; Lidke KA; Lidke DS
    Mol Biol Cell; 2015 Nov; 26(22):4087-99. PubMed ID: 26337388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.